Clinuvel Pharmaceuticals (UR9) Financial Statements
Clinuvel Pharmaceuticals Financial Overview
Clinuvel Pharmaceuticals 's market cap is currently $228.65M. The company's EPS TTM is $0.68; its P/E ratio is 10.62; and it has a dividend yield of 0.69%. Clinuvel Pharmaceuticals is scheduled to report earnings on February 23, 2027, and the estimated EPS forecast is $0.16. See an overview of income statement, balance sheet, and cash flow financials.
| Jun 26 | Jun 25 | Jun 24 | Jun 23 | Jun 22 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 94.02M | $ 95.02M | $ 88.18M | $ 78.32M | $ 65.72M |
| Gross Profit | $ 78.21M | $ 79.14M | $ 80.45M | $ 50.59M | $ 46.62M |
| Operating Income | $ 40.53M | $ 45.73M | $ 48.01M | $ 40.91M | $ 33.08M |
| EBITDA | $ 41.52M | $ 57.20M | $ 56.28M | $ 46.37M | $ 35.08M |
| Net Income | $ 33.92M | $ 36.17M | $ 35.64M | $ 30.60M | $ 20.88M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 252.06M | $ 224.11M | $ 183.87M | $ 156.81M | $ 121.51M |
| Total Assets | $ 296.15M | $ 271.75M | $ 231.12M | $ 194.52M | $ 144.81M |
| Total Debt | $ 1.94M | $ 528.53K | $ 879.78K | $ 999.87K | $ 1.26M |
| Net Debt | $ -18.49M | $ -223.58M | $ -182.99M | $ -22.87M | $ -26.15M |
| Total Liabilities | $ 23.27M | $ 30.94M | $ 28.11M | $ 29.89M | $ 19.25M |
| Stockholders' Equity | $ 272.88M | $ 240.81M | $ 203.01M | $ 164.63M | $ 125.56M |
| Cash Flow | |||||
| Free Cash Flow | $ 35.31M | $ 40.80M | $ 31.48M | $ 35.88M | $ 39.44M |
| Operating Cash Flow | $ 36.91M | $ 41.10M | $ 37.05M | $ 36.91M | $ 39.87M |
| Investing Cash Flow | $ -39.12M | $ -47.72M | $ -29.03M | $ -1.03M | $ -434.44K |
| Financing Cash Flow | $ -2.75M | $ -2.94M | $ -3.57M | $ -2.24M | $ -1.50M |
Currency in AUD